Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
September 12 2022 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
September 12, 2022
Commission File Number: 001-39363
IMMATICS N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K
On September 10, 2022, Immatics N.V. (the “Company”
or “Immatics”) announced a comprehensive preclinical data set for its T cell engaging receptor (TCER®) product candidate
IMA402 at the European Society for Medical Oncology (ESMO) Congress 2022 held in Paris, France, from September 9 to 13, 2022. Data highlights
include:
| · | The IMA402 TCER® utilizes a high-affinity TCR designed to specifically bind to an HLA-A*02:01-presented peptide derived from PRAME
on tumor cells |
| · | The T cell recruiter domain is a proprietary low-affinity T cell recruiter against the TCR/CD3 complex that demonstrates superior
in vivo tumor control compared to analogous TCER® molecules designed with higher-affinity variants of a widely used antibody
recruiter |
| · | The IMA402 TCER® is optimized to reduce T cell engager-associated toxicities in patients, which is demonstrated by reduced recruiter-mediated
cytokine release in vitro |
| · | IMA402 showed potent and selective activity against PRAME-positive tumor cell lines in vitro |
| · | In vivo studies in mice demonstrated dose-dependent anti-tumor activity of IMA402. Sufficiently high drug doses were key to
achieving the desired anti-tumor effects over a prolonged period |
| · | In vitro safety assessment including toxicity screening against 20 normal tissue types, whole blood cytokine release assessment
and alloreactivity evaluation confirmed favorable safety profile for IMA402 |
| · | The half-life extended format of IMA402 confers a serum half-life of >1 week in mice suggesting a favorable dosing regimen and
prolonged drug exposure at therapeutic levels when compared to TCR Bispecifics lacking half-life extension strategies |
| · | IMA402 is designed to allow high dosing not limited by toxicities with the goal of reaching relevant therapeutic doses in tumor tissue
and achieve a meaningful clinical benefit in patients |
A clinical trial evaluating IMA402 in patients
with solid tumors is expected to start in 2023. The Phase 1 part of the trial will start with a minimal anticipated biological effect
level (MABEL) dose of IMA402 and will have an adaptive design aimed at accelerating dose escalation to determine the recommended Phase
2 dose (RP2D). HLA-A*02:01-positive patients with different solid tumors expressing PRAME will initially receive weekly infusions of IMA402.
Pharmacokinetics data will be assessed throughout the trial and might provide an opportunity to adapt the treatment interval. The Phase
2a dose expansion part of the trial will be designed to comprise several cohorts to further evaluate IMA402 in specific indications and
combination therapies. Submission of the IND application is planned for Q2 2023.
In connection with the foregoing, the Company issued
a press release, a copy of which is attached hereto as Exhibit 99.1.
INCORPORATION BY REFERENCE
This Report on Form 6-K (other than Exhibit 99.1)
shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-258351 and 333-240260)
of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports
subsequently filed or furnished.
EXHIBIT INDEX
Exhibit No. |
Description |
99.1 |
Press release dated September 10, 2022 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
IMMATICS N.V. |
|
|
Date: September 12, 2022 |
|
|
By: |
/s/ Harpreet Singh |
|
Name: |
Harpreet Singh |
|
Title: |
Chief Executive Officer |
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Sep 2023 to Sep 2024